Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report

Pulmonary sarcomatoid carcinoma (PSC), characterized by poor differentiation, aggressive progression, and early metastasis, is a rare type of non‐small cell lung carcinoma (NSCLC), which shows a low response rate to conventional antitumor therapies and has a poor prognosis. With the achievements in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Li, Tao, Ning‐ning, Liang, Bin, Li, Dao‐wei, Li, Huai‐chen, Su, Li‐li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807335/
https://www.ncbi.nlm.nih.gov/pubmed/34953097
http://dx.doi.org/10.1111/1759-7714.14290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807335/
https://www.ncbi.nlm.nih.gov/pubmed/34953097
http://dx.doi.org/10.1111/1759-7714.14290

Ejemplares similares